Desmoplastic Squamous Cell Carcinoma

Desmoplastic carcinoma; desmoplastic cutaneous squamous cell carcinoma

A rare, aggressive variant of cutaneous squamous cell carcinoma characterized by a pronounced desmoplastic stromal reaction. It is associated with a high risk of local recurrence and metastasis (~25%).

A very rare entity, primarily affecting elderly adults with chronic sun exposure. Males are more frequently affected than females.

No formal subclassification exists. Considered a high-risk subtype of cutaneous squamous cell carcinoma.

Chronic UV exposure is the main etiological factor. Additional risk factors include immunosuppression, chronic wounds, HPV infection, and genetic predispositions (e.g., xeroderma pigmentosum). Pathogenetically, atypical keratinocytes infiltrate into a dense, fibrotic desmoplastic stroma.

Clinically presents as indurated, poorly demarcated, skin-colored to erythematous papules, plaques, or nodules. Often slow-growing. Lesions may ulcerate and exhibit infiltrative growth. Local recurrence and perineural invasion are common.

Based on clinical examination, including palpation of regional lymph nodes. Histological confirmation via biopsy. Lymph node ultrasound or sentinel lymph node biopsy is recommended in high-risk cases. MRI is useful for detecting perineural spread in suspected recurrences.

Commonly found in chronically sun-exposed areas such as the face, ears, scalp, lower lip, and dorsum of the hands.

Slowly enlarging, firm nodule in sun-exposed skin, often over months or years. Patients often have a history of cryotherapy or topical treatment.

Infiltrating nests of atypical, pleomorphic keratinocytes surrounded by dense, collagen-rich desmoplastic stroma. Perineural invasion is frequent. Immunohistochemistry may show positivity for p63, CK5/6, and EMA.

Local tissue destruction, high recurrence rates, lymphatic and visceral metastases. Perineural spread may cause neurological symptoms.

Sun protection, regular skin self-examination, and dermatologic monitoring in high-risk individuals

Worse than conventional squamous cell carcinoma. Local recurrence in up to 25% of cases. Prognosis depends on tumor thickness, degree of differentiation, invasion depth, and adequacy of treatment.

First-line therapy:

• Microscopically controlled excision (Mohs surgery) with 3–5 mm surgical margins

• Conventional excision with histologically confirmed R0 status

• Sentinel lymph node biopsy in high-risk patients

• Radiotherapy in inoperable cases, recurrences, or perineural invasion (ED 2 Gy, total 50–74 Gy)

Additional options:

• Curettage and electrodessication (small, superficial lesions)

• Cryotherapy (less suitable for infiltrative tumors)

• Topical or intralesional chemotherapy (e.g., 5-FU, imiquimod) only for in situ or superficial lesions

• Systemic therapy (e.g., cetuximab, chemotherapy) in metastatic disease

1. Breuninger H. Cutaneous squamous cell carcinoma. AWMF guideline 032-022.

2. Brantsch KD, et al. Risk factors determining prognosis of cutaneous SCC. Lancet Oncol. 2008;9:713-20.

3. Garcia-Zuazaga J, Olbricht SM. Cutaneous SCC. Adv Dermatol. 2008;24:33-57.

4. Veness MJ, et al. High-risk cutaneous SCC of head and neck. Cancer. 2006;106:2389-96.

5. Geist DE, et al. Perineural invasion of cutaneous SCC. Dermatol Surg. 2008;34:1642-51.

6. Morton C, et al. PDT vs cryotherapy/5-FU for SCC in situ. Arch Dermatol. 2006;142.

7. Patel GK, et al. Imiquimod monotherapy for SCC in situ. J Am Acad Dermatol. 2006;54:1025-32.

8. Veness MJ, et al. SCC metastatic to parotid and cervical nodes. Head Neck. 2007;29:621-31.

9. Love WE, et al. Topical Imiquimod or 5-FU for SCC. Arch Dermatol. 2009;145.

10. Cowen EW, et al. Voriconazole-induced aggressive SCC. J Am Acad Dermatol. 2010;62:31-7.